(Reuters) – Inovio Pharmaceuticals on Monday said its COVID-19 vaccine candidate was safe, well-tolerated and produced immune response against the coronavirus in all tested age groups in a mid-stage clinical trial.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)
